Unibloc Pump Rebrands to Unibloc Hygienic Technologies
Unibloc Pump, a leader in positive displacement pumps and other highly engineered products for demanding hygienic flow control applications, has rebranded to Unibloc Hygienic Technologies (UHT). The rebranding follows the company’s expansion of its family of hygienic flow control brands, most recently through its acquisitions of Flotronic Pumps and Standard Pump.
- Flotronic Pumps: UK-based manufacturer of specialized, air-operated double diaphragm (AODD) pumps and associated accessories primarily for hygienic flow control applications (acquired by Unibloc Pump in August 2021)
- Standard Pump: Georgia-based manufacturer of hygienic and industrial process pumps, including drum pumps and other fluid handling equipment (acquired by Unibloc Pump in December 2021)
"All three companies – Unibloc, Flotronic, and Standard Pump – have each built a leading reputation for quality manufacturing, innovative design and excellent customer service,” said Chris Stevens, CEO of Unibloc Hygienic Technologies. “Our new market identity communicates to customers that today we offer a much more expansive line of hygienic product solutions for a wider variety of applications. No other company can match the process and application experience the UHT team brings to our customers.”
Each company’s products are represented now as subsidiary brands under the Unibloc Hygienic Technologies umbrella, with identities that tie them together. Additionally, a new brand, Hygenitec, has been created to represent a range of additional hygienic flow control products, such as valves, strainers, sight glasses, drum pumps and bubble traps.
“Customers are more time-pressed than ever before, and more focused on building best-in-class systems in their facilities,” said Mark Boyd, vice president of sales at Unibloc Hygienic Technologies. “As a result, we have designed our approach to the market to make it simpler and faster for customers to get the information they need on a wider variety of product solutions, all from a single company and a single point of contact.”
About Unibloc Hygienic Technologies
An industry leader in flow control technology and performance, Unibloc Hygienic Technologies offers precision-engineered positive displacement pumps, AODD pumps, drum pumps, and other highly engineered products for demanding hygienic flow control applications. UHT serves a variety of hygienic industries, including food, beverage, bakery/confection, meat and poultry, brewery, pharmaceutical, and transportation, under the Unibloc, Flotronic, Standard Pump, and Hygenitec subsidiary brands. UHT’s highly efficient, easy-to-maintain products help customers fight downtime, achieve a lower cost of operation, and meet deadlines with confidence. Learn more at www.unibloctech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005207/en/
Contact information
Joel Goldstein
216-509-3119
jgoldstein@ggcomm.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com